Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
Developer of an optical testing product intended for postoperative monitoring and treatment. The company's product makes the postoperative management of dislocated intraocular lenses intuitive and straightforward, enabling patients to reduce post-operative refractive issues after cataract surgery.
Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.
Restore Medical develops and provides a device-based therapy for congestive heart failure. It improves patient quality of life and reduce hospital readmission rates. Restore Medical's product, ContraBand, is a novel catheter-delivered implant in the pulmonary arteries for treatment of left ventricle failure, for patients with preserved right ventricle function. Restore Medical was founded in 2016 and is headquartered in Or Yehuda, Israel.
IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
Oivi develops an easy and affordable AI-camera and platform that will identifies diabetic eye-disease. It allows retinal screening at primary care, creating awareness, and maintaining diabetic eye-health for all. The company has a multifaceted team with extensive knowhow on camera and software development.
Oivi was founded on 2017 and is headquartered in Oslo, Norway.
GlucoSet AS is a medical device company based in Trondheim, Norway, specializing in the design and manufacturing of sensor-based blood glucose monitoring tools for use in Intensive Care Units (ICUs). Founded in 2011, GlucoSet focuses on developing intravascular sensor technology that provides continuous and accurate monitoring of blood glucose levels in critically ill patients. This technology addresses the challenges of elevated and unstable glucose levels in ICU settings, which can lead to costly complications, prolonged hospital stays, and increased mortality rates. By delivering real-time glucose information, GlucoSet's system enables healthcare professionals to effectively manage glucose levels, thereby minimizing the risk of harmful hypoglycemia and improving overall patient outcomes.
Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.
OxyPrem AG is a Swiss company that develops, designs, and manufactures advanced sensor solutions specifically for monitoring preterm infants. Founded in 2018 and based in Zurich, it offers a reusable oxygen sensor that continuously measures hemoglobin oxygen saturation in any human tissue, particularly focusing on the brains of high-risk preterm infants. By employing noninvasive near-infrared light technology, the device provides real-time monitoring, enabling healthcare professionals to prevent severe outcomes such as early death or long-term brain damage in this vulnerable population. OxyPrem's innovative approach not only enhances clinical care but also significantly reduces medical waste associated with single-use devices.
Legacy Healthcare is a biopharma company focused on the development of oncology supportive care and dermatology drugs
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately so that treatment options for cancer patients and their long-term survival can be significantly improved.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.
Qnami AG manufactures non-invasive sensors. Its products include ProteusQ, non-invasive magnetic imaging microscope; and Quantum Diamond, which includes Quantilevers MX, diamond probes containing a single NV for high resolution magnetic imaging, and NV diamond membranes, ready-to-use diamond with NV centers. Its applications are multiferroic antiferromagnet, antiferromagnetic ram, microwave imaging, magnetic nanomemories, and superconductivity. Qnami AG was founded in 2017 and is based in Basel, Switzerland.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.
BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath. The company provides breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using it to diagnose and monitor chronic diseases. It was founded in 2015 and headquartered in South San Francisco, California.
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.
The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
enGenome is a bioinformatics company provides accurate omics-based reports to physicians, thus improving diagnosis and treatment processes for patients. Their products and services helps to improve the diagnosis of genetic diseases and patients therapies by producing accurate genetic reports.
Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.
Positrigo AG develops and manufactures brain PET scanners. It offers solutions for providing functional brain positron emission tomography scans to the masses for the early detection of Alzheimer's disease. The company was founded in 2018 and is based in Zurich, Switzerland.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders. We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate as in-lab sleep studies, at a fraction of the cost. Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases. Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Delmic B.V., based in Delft, the Netherlands, specializes in manufacturing correlative light and electron microscopy solutions aimed at advancing life and materials science research. The company’s primary products include SECOM, which integrates fluorescence and electron microscopy; SPARC, a high-performance cathodoluminescence detection system; and Delphi, a combined fluorescence and scanning electron microscope. Delmic also develops software designed to facilitate navigation within its integrated microscopy systems. Founded in 2010, the company is committed to providing effective and user-friendly tools that enhance research capabilities, enabling researchers and organizations to gain insights more efficiently.
HumanITcare is a digital health company delivering a telemedicine platform for monitoring remotely real-life data of chronic patients using Artificial Intelligence. HumanITcare is improving clinical outcomes and reducing clinical costs by providing an accurate remote patient monitoring system.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.
Smart4Diagnostics GmbH is a Munich-based company founded in 2018 that specializes in the production of digital data fingerprints for human blood samples. The company has developed a device designed for precise blood sample measurement, aiming to enhance the accuracy and reliability of diagnostic processes. By focusing on innovative solutions in the medical technology sector, Smart4Diagnostics contributes to advancements in healthcare diagnostics.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
Positrigo AG develops and manufactures brain PET scanners. It offers solutions for providing functional brain positron emission tomography scans to the masses for the early detection of Alzheimer's disease. The company was founded in 2018 and is based in Zurich, Switzerland.
Resistell is a antibiotic resistance test.
At Quantib we come to work every day to help physicians solve the hardest challenges they face when diagnosing patients. Our smart software analyzes medical images to unravel secrets hidden to the naked eye. Are you excited to learn more about how artificial intelligence techniques can move healthcare forward and help our marketing department tell this story to the world? We’d love for you to join our tight team of 22 conquering the medical world with deep learning software.
Onera B.V. specializes in providing sleep diagnostic solutions aimed at diagnosing sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and based in Eindhoven, the Netherlands, the company employs innovative sleep diagnostic patch systems that collect and analyze sleep data to facilitate accurate diagnoses. These systems are designed to be comfortable and user-friendly, akin to wearing a band-aid, making them accessible for patients. Onera B.V. is a spin-off of imec, a leading research center in nanoelectronics and digital technology, and focuses on advancing sleep medicine through its breakthrough solutions. With a mission to improve the health and quality of life for individuals suffering from sleep-related ailments, Onera aims to provide essential diagnostic services that address the needs of millions worldwide.
SiriusXT Limited, incorporated in 2015 and headquartered in Dublin, Ireland, specializes in the development and manufacture of a soft x-ray microscope known as the SXT system. This innovative benchtop system enables researchers to produce high-resolution images of biological samples in their own laboratories. Utilizing a vacuum-based laser-produced plasma soft x-ray light source, the SXT system facilitates soft x-ray tomography, akin to a CT scan for cells, which is essential for life scientists studying the 3D internal structures of cells in their natural, fully hydrated states. The SXT system is primarily marketed to researchers in disease research and drug discovery, including pharmaceutical companies, biotechnologists, and clinicians, helping them to better understand disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray tomography system, it can produce detailed 3D tomographs of entire cells in minutes.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
Developer of a medical platform intended to deliver clinical decision support for remote care of heart patients with pacemakers. The company's platform leverages machine learning and ethnography to monitor cardiac devices remotely and uses advanced analytics to predict health conditions, enabling chronic patients with digital healthcare that monitors implanted cardiac devices.
SwissDeCode Sàrl, founded in 2016 and based in Renens, Switzerland, specializes in providing rapid on-site DNA testing solutions for the food industry. The company focuses on ensuring food safety and authenticity by offering plug-and-play testing services that allow food manufacturers to receive quality and safety certifications within the same work shift. This capability enables immediate decision-making regarding food authenticity and compliance, helping to transform potential contamination risks into sustainable opportunities for producers. By validating the integrity of the food supply chain, SwissDeCode supports food manufacturers in delivering safe and reliable products to consumers.
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.
The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
SiriusXT Limited, incorporated in 2015 and headquartered in Dublin, Ireland, specializes in the development and manufacture of a soft x-ray microscope known as the SXT system. This innovative benchtop system enables researchers to produce high-resolution images of biological samples in their own laboratories. Utilizing a vacuum-based laser-produced plasma soft x-ray light source, the SXT system facilitates soft x-ray tomography, akin to a CT scan for cells, which is essential for life scientists studying the 3D internal structures of cells in their natural, fully hydrated states. The SXT system is primarily marketed to researchers in disease research and drug discovery, including pharmaceutical companies, biotechnologists, and clinicians, helping them to better understand disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray tomography system, it can produce detailed 3D tomographs of entire cells in minutes.
Operator of an online medical platform intended to help doctors by making informed decisions around clinical diagnosis. The company's platform catalogs clinical information from peer-reviewed medical literature and utilizes artificial intelligence diagnostic engines to extract relevant insights, enabling doctors to map clinical knowledge for fast and informed clinical decision-making.
PKvitality is a bio-wearable company based in Paris, France, founded in 2017. The company has developed K’Track, a line of trackers that utilize its patented SKinTaste technology to analyze physiological markers through non-invasive skin testing, eliminating the need for blood samples. One of its flagship products, K’Watch Glucose, enables diabetic individuals to monitor their glucose levels continuously and conveniently, without the discomfort associated with traditional blood tests. The wearable device features a sensor that requires no calibration, provides a comprehensive data history, and sends alerts to users to remind them to check their glucose levels, enhancing the self-monitoring experience for diabetic patients.
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.
The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Oivi develops an easy and affordable AI-camera and platform that will identifies diabetic eye-disease. It allows retinal screening at primary care, creating awareness, and maintaining diabetic eye-health for all. The company has a multifaceted team with extensive knowhow on camera and software development.
Oivi was founded on 2017 and is headquartered in Oslo, Norway.
MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
MindPeak GmbH is a Hamburg-based company founded in 2018 that specializes in developing software tools for visual diagnosis using artificial intelligence and deep learning. Its primary focus is on assisting pathologists in achieving reproducible cancer diagnostics. One of its key products, BreastAI, quantifies breast cancer immunohistochemistry (IHC) and can be integrated as a service within third-party software applications. MindPeak also optimizes workflows in pathological analysis, demonstrating its commitment to enhancing efficiency in the field. The company maintains a strategic partnership with Gestalt Diagnostics, further expanding its collaborative efforts in advancing diagnostic technologies.
Aiforia Technologies was founded as a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki in 2013 by researchers and pioneers in the field of cloud-based microscopy and pathology and experienced life science entrepreneurs. The Aiforia® Platform brings together deep learning AI and high-performance cloud computing. Aiforia assists with the increased demand for image-based diagnostics by providing efficient and scalable solutions – enabling new discoveries and clinical support with highly accurate and consistent data. Aiforia is technologically driven establishment and keeps the capability of being image agnostic thus extending its solutions to multiple fields.
Bluedrop Medical Limited, founded in 2014 and based in Galway, Ireland, develops and commercializes an Internet of Things-enabled device that facilitates early detection of diabetic foot ulcers. The device conducts daily scans of patients' feet and transmits the data to the cloud for analysis using advanced algorithms. This technology is designed to identify skin abnormalities early, thereby reducing the risk of amputation, a serious complication faced by many diabetics due to peripheral neuropathy. With an estimated 25% of diabetics likely to develop foot ulcers, the company's innovation addresses a critical healthcare need and aims to improve patient outcomes while potentially lowering healthcare costs associated with diabetes-related amputations.
Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.
Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.